| Japanese |
|---|
| Title | ガリウムヒトフィブリノーゲン (67Ga) 注射液の体内での安定性の評価 - ラットにおける血中放射能成分の分析 - |
|---|
| Subtitle | 研究速報 |
|---|
| Authors | 高橋啓悦*, 高橋淳*, 岡野栄*, 倉見美規*, 上田信夫*, 葉杖正昭* |
|---|
| Authors(kana) | |
|---|
| Organization | *日本メジフィジックス株式会社技術部 |
|---|
| Journal | 核医学 |
|---|
| Volume | 24 |
|---|
| Number | 12 |
|---|
| Page | 1771-1774 |
|---|
| Year/Month | 1987/12 |
|---|
| Article | 報告 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「I. 緒言」近年, モノクロナール抗体などの生理活性タンパク質の放射性金属核種を用いた標識にBifunctional Chelating Agent(以下BCAと略す)が用いられるようになった. われわれは, このBCA法をさらに展開し, 反応性高分子を介して, 多数のBCAをタンパク質に結合させるクラスター法を開発した. 反応性高分子として, ジアルデヒドデンプン(DAS)を選択し, BCAであるデフェロキサミン(DFO)をヒトフィブリノーゲンに導入した. これに67Gaを加えて標識されたガリウムヒトフィブリノーゲン(67Ga)注射液(以後67Ga-Fibと略す)は, 高いclottabilityを有し, 臨床的にも血栓診断剤としての有用性が示されつつある. 今回, 本剤の体内での安定性を評価する目的で, ラットの血中放射能成分の検索を行ったので報告する. 「II. 試料および方法」「1. ヒトフィブリノーゲン-DAS-DFO凍結乾燥品(Fib凍結乾燥品)の製造」 |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | Deferoxamine, Ga-67 human fibrinogen, Cluster method, Human fibrinogen, Fib-DAS-DFO. |
|---|
| English |
|---|
| Title | Evaluation of in Vivo Stability of Ga-67 Labeled Human Fibrinogen ; Analysis of Plasma Radioactivity Using Rats |
|---|
| Subtitle | - Rapid Communication - |
|---|
| Authors | Keietsu TAKAHASHI, Jun TAKAHASHI, Sakae OKANO, Miki KURAMI, Nobuo UEDA, Masaaki HAZUE |
|---|
| Authors(kana) | |
|---|
| Organization | Technical Department, Nihon Medi-Physics, Co., Ltd. |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 24 |
|---|
| Number | 12 |
|---|
| Page | 1771-1774 |
|---|
| Year/Month | 1987/12 |
|---|
| Article | Report |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | Human fibrinogen (Fib) was conjugated with a large number of deferoxamine (DFO) through dialdehyde starch (DAS), and the conjugate (Fib-DAS-DFO) was labeled with Ga-67. Thus labeled fibrinogen (Ga-67-Fib-DAS-DFO) showed a high labeling efficiency (more than 90%) and retained clottability (more than 80%). For the evaluation of plasma radioactive species, blood samples were collected at various time periods after the i. v. administration of Ga-67-Fib-DAS-DFO into rats, and the plasma radioactivity was analyzed by high performance liquid chromatography (HPLC) and electrophoresis (EP). The radioactive HPLC elution profiles for the plasma samples were identical with that of the original Ga-67-Fib-DAS-DFO; the EP patterns for the plasma were also identical with the original one, and no radioactive species, except for Ga-67-Fib-DAS-DFO, was detected by HPLC or EP. Furthermore, the presence of transferrin in the labeling formulation did not affect the labeling yield of Ga-67-Fib-DAS-DFO indicating that the transchelation of Ga-67 from DFO on Fib to transferrin is negligible. These findings indicated that Ga-67 is tightly bound to Fib-DAS-DFO in blood, and the Ga-67-Fib-DAS-DFO can be efficiently trapped by clots as the result of its high retention of physiological activities as fibrinogen. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | Deferoxamine, Ga-67 human fibrinogen, Cluster method, Human fibrinogen, Fib-DAS-DFO. |
|---|